Production (Stage)
NLS Pharmaceutics AG
NLSP
$2.30
$0.2210.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -45.51% | -37.80% | -30.83% | -20.10% | -9.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -69.20% | -61.96% | -56.00% | -39.25% | -23.74% |
| Operating Income | 69.20% | 61.96% | 56.00% | 39.25% | 23.74% |
| Income Before Tax | 83.73% | 68.97% | 57.36% | 41.29% | 26.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 83.73% | 68.97% | 57.36% | 41.29% | 26.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 83.73% | 68.97% | 57.36% | 41.29% | 26.21% |
| EBIT | 69.20% | 61.96% | 56.00% | 39.25% | 23.74% |
| EBITDA | 69.24% | 62.01% | 56.05% | 39.28% | 23.76% |
| EPS Basic | 77.00% | 71.71% | 68.55% | 65.53% | 63.70% |
| Normalized Basic EPS | 78.23% | 70.82% | 66.05% | 63.50% | 62.00% |
| EPS Diluted | 77.00% | 71.71% | 68.55% | 65.53% | 63.70% |
| Normalized Diluted EPS | 78.23% | 70.82% | 66.05% | 63.50% | 62.00% |
| Average Basic Shares Outstanding | 61.70% | 47.52% | 29.96% | 54.90% | 93.96% |
| Average Diluted Shares Outstanding | 61.70% | 47.52% | 29.96% | 54.90% | 93.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |